The annualized rate of the primary end point during treatment was @ % with warfarin ( median time in the therapeutic range , @ % ) , as compared with @ % with high-dose edoxaban ( hazard ratio , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P < @ for noninferiority ) and @ % with low-dose edoxaban ( hazard ratio , @ ; @ % CI , @ to @ ; P = @ for noninferiority ) .